Insight is provided into the role of the activated stroma in PDAC, and how SHH acts to mediate this response, and several candidates that are interesting therapeutic targets for a disease for which treatment options are still inadequate are yielded.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, characterized by extensive desmoplasia, aggressive metastasis, and profound therapeutic resistance driven by its tumor microenvironment (TME). Increasing evidence suggests that cancer–stromal interactions, particularly those involving can...
Hui-Lan Chang, Chin-Chun Chang, Gita Riswana Nawung Rida et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer type with a 5-year survival rate of only 13%. PDAC is unique in that up to 90% of the tumor bulk is comprised of a dense desmoplastic stroma. Enriched within PDAC’s extensive stroma are cancer-associated fibroblasts (CAFs). CAFs orchestrate tumor progression...
Marta R. Storl-Desmond, Nicole Liu, K. Forti et al.· Cancer Research· 0 citations
It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.
Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al.· Cancer Research· 0 citations
Intratumoral heterogeneity is a defining feature of pancreatic ductal adenocarcinoma (PDAC), yet how distinct malignant cell states contribute to tumor behavior and stromal diversity in situ remains poorly understood. PDAC contains recurrent classical and basal states, with basal-dominant tumors associated with aggre...
Kate Ryan, A. Singhal, Samuel A. Rose et al.· Cancer Research· 0 citations
A unified four-stage mechanistic model of PNI is proposed, encompassing mutual chemotaxis between tumors and nerves, adhesion and invasion at the tumor-nerve interface, extracellular matrix remodeling, and neural plasticity alterations, and defines the perineural invasion microenvironment as a neuro-immune privileged s...
Wei-Zuo Cheng, Hao-Tian Cao, Hao Hu et al.· Molecular Biomedicine· 0 citations
Pancreatic ductal adenocarcinoma (PDAC), notorious for its fatality, claims a five-year survival rate of around 13%. PDAC is projected to become the second leading cause of cancer-related deaths by 2030. PDAC is often diagnosed at the advanced stage, where the tumor has spread to distant organs such as the liver and...
Natalia Ramirez-Sotelo, Reegan A. J. Miller, Damian P. Matysniak et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
